Pharming Group (NASDAQ:PHAR) Sees Strong Trading Volume – Should You Buy?

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) shares saw unusually-high trading volume on Tuesday . Approximately 16,852 shares traded hands during trading, a decline of 9% from the previous session’s volume of 18,556 shares.The stock last traded at $11.4550 and had previously closed at $11.35.

Analyst Ratings Changes

Several research firms have issued reports on PHAR. Oppenheimer reaffirmed an “outperform” rating on shares of Pharming Group in a research report on Thursday, July 30th. Wall Street Zen lowered shares of Pharming Group from a “strong-buy” rating to a “hold” rating in a research note on Saturday, May 9th. Canaccord Genuity Group raised their target price on shares of Pharming Group from $37.00 to $38.00 and gave the company a “buy” rating in a research note on Monday, August 3rd. Weiss Ratings reiterated a “sell (d)” rating on shares of Pharming Group in a report on Friday. Finally, Zacks Research lowered Pharming Group from a “hold” rating to a “strong sell” rating in a research note on Friday, July 31st. Three analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $38.67.

Pharming Group Stock Up 1.5%

The company has a market cap of $815.60 million, a P/E ratio of 96.03 and a beta of -0.01. The stock has a 50-day moving average of $12.71 and a 200 day moving average of $14.84. The company has a debt-to-equity ratio of 0.34, a current ratio of 3.01 and a quick ratio of 2.31.

Pharming Group (NASDAQ:PHAR) last released its earnings results on Thursday, July 30th. The company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.06 by ($0.04). The firm had revenue of $90.20 million during the quarter, compared to the consensus estimate of $99.52 million. Pharming Group had a net margin of 2.51% and a return on equity of 3.40%. Research analysts anticipate that Pharming Group N.V. Sponsored ADR will post 0.25 earnings per share for the current year.

Hedge Funds Weigh In On Pharming Group

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. EverSource Wealth Advisors LLC acquired a new stake in Pharming Group in the second quarter valued at approximately $32,000. SmartHarvest Portfolios LLC acquired a new position in shares of Pharming Group during the fourth quarter worth $224,000. Millennium Management LLC bought a new position in shares of Pharming Group in the 4th quarter valued at $360,000. Finally, NewEdge Advisors LLC lifted its stake in shares of Pharming Group by 11,310.3% in the 4th quarter. NewEdge Advisors LLC now owns 28,868 shares of the company’s stock valued at $510,000 after acquiring an additional 28,615 shares during the last quarter. Institutional investors own 0.03% of the company’s stock.

Pharming Group Company Profile

Pharming Group N.V. is a clinical-stage biopharmaceutical company headquartered in Leiden, the Netherlands, with a primary focus on developing and commercializing innovative protein replacement therapies for patients living with rare diseases. The company employs a proprietary transgenic technology platform designed to produce recombinant human proteins in the milk of transgenic animals, enabling scalable and cost-efficient manufacturing of complex therapeutic proteins.

The company’s lead product, RUCONEST (recombinant human C1 esterase inhibitor), is approved for the treatment of acute hereditary angioedema (HAE) attacks in multiple markets, including the United States and Europe.